Profound Medical
Financials
Estimates*
CAD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 10.0m | 9.4m | 9.1m | 9.8m | 15.4m | 38.9m | 65.2m |
% growth | 135 % | (6 %) | (3 %) | 8 % | 57 % | 152 % | 68 % |
EBITDA | (22.7m) | (38.7m) | (34.7m) | (35.4m) | (36.8m) | (18.3m) | 1.7m |
% EBITDA margin | (228 %) | (413 %) | (381 %) | (361 %) | (239 %) | (47 %) | 3 % |
Profit | (29.5m) | (41.9m) | (39.1m) | (39.0m) | (39.2m) | (29.8m) | (22.6m) |
% profit margin | (296 %) | (447 %) | (429 %) | (397 %) | (254 %) | (77 %) | (35 %) |
EV / revenue | 51.6x | 31.6x | 33.2x | 24.7x | 19.6x | 7.8x | 4.6x |
EV / EBITDA | -22.7x | -7.7x | -8.7x | -6.8x | -8.2x | -16.6x | 181.6x |
R&D budget | 13.5m | 20.8m | 20.0m | 19.6m | - | - | - |
R&D % of revenue | 136 % | 222 % | 220 % | 200 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
CAD9.4m | Series A | ||
CAD28.0m | Late VC | ||
N/A | N/A | IPO | |
N/A | N/A | IPO | |
* | N/A | $30.0m | Post IPO Equity |
* | N/A | Post IPO Equity | |
Total Funding | €24.9m |
Recent News about Profound Medical
EditProfound Medical is a pioneering healthcare company specializing in customizable, incision-free ablation therapies. The company leverages advanced technologies such as real-time Magnetic Resonance (MR) Imaging, thermal ultrasound, and closed-loop temperature feedback to offer innovative treatment solutions. Profound Medical primarily serves healthcare providers and patients, focusing on conditions like prostate cancer. Operating in the medical technology market, the company employs a business model centered around the development, manufacturing, and sale of its proprietary therapy platforms. Revenue is generated through the sale of medical devices and related services, including training and support for healthcare professionals.
Keywords: ablation therapies, MR imaging, thermal ultrasound, prostate cancer, healthcare, medical technology, non-invasive, customizable treatments, closed-loop feedback, medical devices.